Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 28 August 2008, doi:10.1136/bmj.a1110
Cite this as: BMJ 2008;337:a1110
Alison Grant, consultant physician, consultant physician 1,2, Philip Gothard, consultant physician1, Guy Thwaites, Wellcome Trust clinician scientist, Wellcome Trust clinician scientist1,3
1 Hospital for Tropical Diseases, University College London Hospitals NHS Foundation Trust, London WC1E 6JB, 2 Clinical Research Unit, London School of Hygiene & Tropical Medicine, London WC1E 7HT, 3 Centre for Molecular Microbiology and Infection, Imperial College, London SW7 2AZ
Correspondence to: A Grant alison.grant@lshtm.ac.uk
| The first 150 words of the full text of this article appear below. |
|
Antituberculosis drug resistance is increasing both in the United Kingdom and internationally.1 2 It has come to greater public attention with the emergence of extensively drug resistant tuberculosis (box 1) in South Africa, where an outbreak proved rapidly fatal among people with advanced HIV infection.3 In this
Global risk factors
Additional risk factors in United Kingdom
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Read all Rapid Responses